Adult Dosing
Acute bacterial skin and skin structure infections (ABSSSI)
- 600 mg IV infusion (over 1hr) q12 hrs x 5-14 days
Community-acquired bacterial pneumonia (CABP)
- 600 mg IV infusion (over 1hr) q12 hrs x 5-7 days
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
Renal Dose Adjustment (Based on CrCl)
- >50 mL/min: No dose adjustments
- >30 -
50 mL/min: 400 mg IV (over 1 hr) q12 hrs 
15 - 30 mL/min: 300 mg IV (over 1 hr) q12 hrs- ESRD and hemodialysis: 200 mg IV (over 1 hr) q12 hrs
Hepatic Dose Adjustment
- Hepatic impairment: No dose adjustments
See Supplemental Patient Information
- Serious and rarely life-threatening hypersensitivity reactions and serious skin reactions have been reported with beta-lactam antibacterials, including ceftaroline. Prior to initiating therapy, determine about previous hypersensitivity reactions to other cephalosporins, penicillinis, or carbapenems
- Discontinue therapy if any allergic reactions occur and institute appropriate medical therapy in case of serious hypersensitivity reactions
- Exercise caution in penicillin or other beta-lactam-sensitive patients due to the risk of cross sensitivity among beta-lactam antibacterial agents
- Clostridium difficile-associated diarrhea, which may vary in severity from mild diarrhea to fatal colitis, has been reported during therapy. Any case of diarrhea following the drug use should be investigated and appropriate therapy should be initiated, if confirmed
- Seroconversion from a negative to a positive direct Coombs' test result has occurred in patients receiving ceftaroline. If anemia develops during or after therapy, a diagnostic workup for drug-induced hemolytic anemia should be considered
- Use in the absence of a proven or strongly suspected bacterial infection may increase the risk of the development of drug-resistant bacteria
Cautions: Use cautiously in
- History of antibiotic-associated colitis
Supplemental Patient Information
- Advise patients to contact their physicians if severe watery or bloody diarrhea develops during therapy
Pregnancy Category:B
Breastfeeding: No information is available regarding its use during breastfeeding. Ceftaroline belongs to cephalosporin class of antibiotics, which are not expected to cause any adverse effects in breastfed infants. Disruption of the infant's GI flora, resulting in diarrhea or thrush have been reported with cephalosporins, but these effects have not been evaluated. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 17 May 2011). Manufacturer advises caution when administered to a nursing woman.
